Here’s what transpired at the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #2, 11/08/2025 —
Key sessions & programs
- A full-day poster session ran from 8:00 a.m.–5:00 p.m. in Hall DE. Topics included diagnostics & biomarkers for steatotic liver disease (MASH/MASLD), epidemiology/natural history, prevention & outcomes.
- A presentation titled “Military Exposures and Liver Disease: What We Know and What’s On the Horizon” took place at 9:00-9:15 a.m. in Room 146A (Level 1).
- A business meeting of the Public Health Special Interest Group (SIG) occurred from 9:45-10:45 a.m. in Room 146A (Level 1).
- Another program: “HepatoTalk: Navigating Difficult Conversations Between Clinicians, Patients, and Families” was scheduled for 3:45-4:45 p.m., in Salon GH (Level 1).
- The Fatty Liver Foundation had activity on this day as well: a poster on shifting trends in U.S. steatotic liver disease care, and a “Community Conversation” via Zoom held at 1:00 – 2:00 p.m. ET. F
Why Day 2 matters for our work with LiverRight
- The focus on steatotic liver disease (MASLD/MASH), diagnostics/biomarkers, and real-world outcomes aligns strongly with our clinic’s mission of early detection and national virtual liver disease care.
- The poster sessions and presentations dealing with diagnostics could offer insights or leads on tools/tests that might integrate with your “Find42™” EMR/Payer Claims Data AI platform and virtual screening strategy.
- The patient-community engagement and SIG business meetings highlight networking and advocacy opportunities—for example, aligning with patient-advocacy groups or influencing guideline evolution.
If you like, I can pull up a detailed breakdown of all the presentations/posters on Day 2 (Nov 8) – for instance, by session code, key authors, and topics most relevant to liver disease screening and virtual care. Would you like me to do that?
At-a-glance
- Poster Sessions (Hall DE): 8:00 AM – 5:00 PM (multiple tracks incl. MASLD/MASH biomarkers; epidemiology/natural history; HBV; ALD; transplant; genetics).
- Meet-Ups @ The Park @ TLM: 9:45–10:45 AM (Foundation awardees, PBC patient, Diversity); 12:30–2:00 PM (Masterclass); Annual Business Meeting 1:00–2:00 PM (Room 206); 3:45–4:45 PM (Clinician & Medical Educators; MASLD/MASH patient).
- Exhibit Hall Opening Reception: 6:00–7:30 PM (Hall D/E).
Scientific & SIG highlights (examples with times/rooms)
- “Military Exposures and Liver Disease: What We Know and What’s On the Horizon” — 9:00–9:15 AM, Room 146A (Level 1).
- Public Health SIG Business Meeting — 9:45–10:45 AM, Room 146A (Level 1).
- HepatoTalk: Navigating Difficult Conversations… — 3:45–4:45 PM, Salon GH (Level 1).
Industry & satellite symposia (select Saturday items)
- A New Era in MASH: How Disease-Specific Therapies Are Changing the Landscape — 12:30–2:00 PM, Convention Center Room 152 (Medscape Education). AASLD
- Connecting the Clues: AATD (Alpha-1) — 12:30–2:00 PM, Room 150 (Takeda/Medscape). AASLD
- Toward Functional Cure in Chronic HBV — 12:30–2:00 PM, Room 147 (GSK/PeerView). AASLD
- MASLD & Cardiometabolic Syndrome: The Dream MDT Team! — 7:30–9:30 PM, Marriott Marquis (Perspectum/HealthProMatch). AASLD
Sessions of Interest
| Time | Session | Focus | Key Details |
|---|---|---|---|
| 8:00-9:00 AM | Hot Topics in Hepatitis B: New Clinical Tools (Room unspecified) AASLD | HBV, noninvasive testing, MASLD overlap | Includes content on HCC risk calculators (e.g., REACH-B, mPAGE, GALAD) AASLD |
| 11:00-12:30 PM | Therapeutic Choices in Hepatology, 2025 (Room 146B, Level 1) AASLD | Case-based discussion | Steatotic liver disease (MASLD/MASH) diagnostics & treatment, HBV guideline update |
| 8:00 AM-5:00 PM | Poster Session: MASLD/MASH – Diagnostics & Biomarkers (Hall DE) UCLA Health | Diagnostics/biomarkers | Sample abstracts: “Hepatology and the Home: A Novel Home-Based Ethnographic Approach …” Abstract 2188 UCLA Health |
| 8:00 AM-5:00 PM | Poster Session: Liver Transplantation and Liver Surgery (Hall DE) UCLA Health | Transplant outcomes | Example: Platelet Recovery After Liver Transplantation: A New Look at Timing and Risk Factors Abstract 3471 UCLA Health |
| 8:00 AM-5:00 PM | Session: HCC Surveillance / Biomarker Landscape AASLD | HCC screening innovation | Focus on blood-based biomarker landscape given limitations of ultrasound |